An observational study in Prostatic Adenocarcinoma, sponsored by University Hospital, Brest. Completed at 2 sites in France. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-12.
Sponsored by University Hospital, Brest · Observational
With 50% of post-operative biochemical failure, efficient predictive models are needed to guide post-operative management.
Radiomic features are quantitative features extracted from medical imaging, supposed to be correlated with tumor heterogeneity.
We aim to build and test three predictive models (clinical, radiomic and combined models).
2,004 studies on the registry are indexed under Adenocarcinoma; 375 are open to participants now.
This study's enrollment of 195 is above the median of 153 across 332 observational studies indexed under Adenocarcinoma.
Browse Adenocarcinoma studies →University Hospital, Brest is the lead sponsor of 594 studies on the registry; 135 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Prediction of biochemical failure
Comparison of AUCs between each predictive model
Time frame: From the date of surgery until data collection (up to 100 months)
Prediction of survival without biochemical failure
Survival analysis: comparison of Kaplan-Meier curves
Time frame: From the date of surgery until data collection (up to 100 months)
Plan to share: Yes — All collected data that underlie results in a publication
Supporting information: Study protocol
No publications or documents are linked to this record.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Brest